scorecardresearchSuven Pharmaceuticals Share Price Live NSE, BSE, Today - Suven Pharmaceuticals
Mintgenie
Asian Paints3,161.35-8.25 (-0.26%)
Axis Bank1,036.755.50 (0.53%)
Bajaj Finance7,809.4072.25 (0.93%)
Bajaj Finserve1,540.451.25 (0.08%)
Bharti Airtel927.302.25 (0.24%)
HCL Technologies1,236.20-6.95 (-0.56%)
HDFC Bank1,526.553.60 (0.24%)
Hindustan Unilever2,467.957.75 (0.32%)
ICICI Bank952.059.35 (0.99%)
ITC444.403.70 (0.84%)
Indusind Bank1,426.2012.80 (0.91%)
Infosys1,435.05-4.45 (-0.31%)
Kotak Mahindra Bank1,735.703.25 (0.19%)
Larsen & Toubro3,021.9510.10 (0.34%)
Mahindra & Mahindra1,553.65-3.05 (-0.20%)
Maruti Suzuki India10,570.353.40 (0.03%)
NTPC245.657.85 (3.30%)
Nestle India22,458.45-64.05 (-0.28%)
Power Grid Corporation Of India199.85-0.90 (-0.45%)
Reliance Industries2,346.5012.50 (0.54%)
State Bank Of India598.708.75 (1.48%)
Sun Pharmaceutical Industries1,159.1026.95 (2.38%)
Tata Consultancy Services3,530.75-6.50 (-0.18%)
Tata Motors630.3516.40 (2.67%)
Tata Steel129.002.25 (1.78%)
Tech Mahindra1,225.00-4.50 (-0.37%)
Titan Company3,149.60-10.95 (-0.35%)
Ultratech Cement8,260.00106.75 (1.31%)
Wipro406.250.45 (0.11%)

Suven Pharmaceuticals

BSE: 543064 | NSE: SUVENPHAR | ISIN: INE03QK01018 | SECTOR: Biotechnology & Drugs

₹561.35 20.70 (3.83%)

29 Sep 2023, 10:10 (IST)

  • Open

    556.95

  • High

    565.35

  • Low

    545.35

  • Prev Close

    540.65

  • P/E

    -

  • Median P/E

    -

  • P/B

    -

  • Median P/B

    -

  • Market Cap

    142.90B

  • Volume

    7.83K

  • Vol. (20 day Avg.)

    0

  • PEG

    -

  • Div.Yield

    -

  • Bid

    -

  • Ask

    -
View all metrics

Company Description

  • Biotechnology & Drugs

  • BSE

    543064

  • NSE

    SUVENPHAR

  • ISIN

    INE03QK01018

Suven Pharmaceuticals Limited is an India-based company. The Company is engaged in the business of development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Specialty Chemicals and formulated drugs under contract research and manufacturing services for global pharmaceutical, biotechnology, and chemical companies. The Company operates through Pharmaceuticals Manufacturing and Services segment. Its geographical segments include India, the United States, Europe, and others. In India, the Company sells bulk drugs and intermediates, chemicals, and services. In the United States, the Company sells intermediates and services. In Europe, the Company sells bulk drugs and intermediates. In other countries, the Company sells bulk drugs, intermediates, and services. The Company’s wholly owned subsidiary is Suven Pharma Inc.

Company Officers

  • K. Rao

    Compliance Officer, Company Secretary

  • Venkateswarlu Jasti

    Managing Director, Executive Director